Analyst Matthew Taylor writes about difficulties, “Based on our channel checks and prior work, we think there is risk around: a) how much DCB's will be used vs. PTA/stenting; b) reimbursement/add-on payments; and c) market share vs. MDT. Our model now contemplates a roughly 20% split for BCR and 80% for MDT in the US.”
Based on these factors, Barclays cut its price target from $155 to $150 (9.6 percent upside). The $150 target is based on 16.5 times 2015 EPS of $9.10. The previous estimate was based on 17 times 2015 EPS of $9.15.
Shares of C.R. Bard are down 0.62 percent to $136.89.
See more from Benzinga
- Benzinga's Top Downgrades
- CR Bard Expands Share Repurchase Program - Analyst Blog
- CR Bard's Lutonix DCB Moves Closer To FDA Clearance - Analyst Blog
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.